GSK Unveils Plans For Major Europe Biotech Cluster
Could Result in Up To 5,000 Jobs
The under-pressure drugs giant has something to cheer with plans for a new campus that could attract several world-class research organizations to its doorstep and bring a multi-million pound windfall from the sale of land.
You may also be interested in...
Moves by Elliott Advisors to split up GSK and unseat Emma Walmsley look unlikely to succeed, but have already created pressure for more deal-making.
Taking full control of partner Translate Bio means that Sanofi is the only big vaccine company with a wholly-owned mRNA platform in-house but observers say it is too early to declare that the Paris-headquartered group has bagged itself a bargain.
Fears that US regulators would take issue with AstraZeneca's decision to change the endpoints of a second pivotal trial for anifrolumab were unfounded and the first-in-class type I interferon inhibitor is the first new treatment for systemic lupus erythematosus in more than 10 years.